Viral Vector & Plasmid DNA Manufacturing Market

Q: What will be the CAGR of the global viral vector & plasmid DNA manufacturing industry during the forecast period?

The CAGR is anticipated to be 15.7% from 2025 to 2035 Read More

Viral Vector & Plasmid DNA Manufacturing Market (Vector Type: Viral Vectors and Plasmid DNA; Workflow: Upstream Manufacturing and Downstream Manufacturing; and Application: Cell and Gene Therapies, Vaccine Development, Antisense & RNAi Therapies and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

Viral Vector & Plasmid DNA Manufacturing Market Outlook 2035

The global viral vector & plasmid DNA manufacturing market size was valued at US$ 4.8 billion in 2024 and is projected to reach US$ 23.9 billion by 2035, expanding at a CAGR of 15.7% from 2025 to 2035. The market growth is driven by increasing adoption of gene therapies for treatment of genetic and rare disorders, technological advancements in manufacturing processes, growing clinical trials and market approvals for gene-based products.

Market Size & Highlights

The viral vector & plasmid DNA manufacturing market reached US$ 4.8 Billion in 2024.
The market is expected to climb to US$ 23.9 Billion by 2035.
The industry is anticipated to expand at a CAGR of 15.7% from 2025 to 2035.
Top companies in the market include Thermo Fisher Scientific Inc., Lonza, Merck KGaA, Takara Bio Inc., Sanofi.
North America dominated the market in 2024, holding the largest revenue share of 43.8%.
By vector type, the viral vectors segment held the major market share of 62.4% in 2024.

Viral Vector & Plasmid Dna Manufacturing Market By Region

Analysts’ Viewpoint regarding Viral Vector & Plasmid DNA Manufacturing Market

The viral vector and plasmid DNA manufacturing market is driven by the growing requirement of specialized therapies, such as gene therapies and vaccines. The growing prevalence of genetic disorders and infectious diseases results in rising demand for novel treatment solutions, further driving the market.

Regulatory pressures for stringent quality standards and detailed analytical characterization further propel investment in dedicated facilities and robust quality systems. The necessity for efficient impurity management and prolonged stability in the case of biologics and vaccine production are the other factors that remarkably influence market dynamics.

Growing partnerships between companies in the contract development and manufacturing organizations (CDMOs) and biopharmaceutical sector is another key driver to the viral vector and plasmid DNA manufacturing market.

Such partnerships provide optimized manufacturing operations as well as access to new technology, thereby boosting efficiency. Additionally, growing focus on personalized medicine is driving the demand for personalized therapy, which further generates the need for diverse production capabilities.

The ongoing trends imply a rapid implementation of flexible manufacturing technologies and customer-centered service models. In order to increase flexibility, mitigate risk of contamination, and shorten the time needed for changeover, single-use bioreactors, perfusion processes, and closed-system workflows are being utilized.

Advancements in downstream purification, facilitated by high-capacity chromatography and nuclease clearance, are further improving throughput and product purity. Contract manufacturers are offering comprehensive end-to-end solutions that combine plasmid supply, vector drug-substance production, and fill/finish connectivity. Regionalization and sustainability measures, such as waste reduction and energy saving, are being recognized as the differentiating factors among service providers in the market.

The competitive landscape is characterized by strategic investments in capacity, standardization, and collaborative partnerships. Market players are investing in the expansion of their multi-site geographical presence and modular facilities as a means of expand geographic presence and rapid response capacity.

The adoption of standardized platforms facilitates technology transfer and lowers regulatory risk, while flexible commercial agreements such as capacity reservation, tolling, and risk-sharing models are mainly used to align incentives. Moreover, the companies are implementing process analytics, automation, workforce upskilling, and proactive regulatory engagement for converting scaling-up into safe and efficient market launches.

Viral Vector & Plasmid DNA Manufacturing Market Introduction

Viral vector and plasmid DNA manufacturing implies the production of essential components of cell therapy, gene therapy, and vaccine technology. Viral vectors are referred to as the genetically modified viruses used for transferring genetic material into cells for providing therapeutic treatment for multiple diseases.

Plasmid DNA is also an essential component for gene expression and vaccine production. The production of viral vectors and plasmid DNA involves design, production, purification, and quality control of these biological reagents. As advancements in biotechnology continue to evolve, the sector plays an important role in addressing unmet medical needs and advancing personalized medicine.

Plasmid DNA manufacturing entails upstream the fermentation of bacterial cultures, especially E. coli, followed by downstream purification steps like lysis, chromatography, and filtration. This method produces highly supercoiled pure plasmid DNA under Good Manufacturing Practice (GMP) standards, thereby ascertaining compliance with regulations regarding uniformity and purity. This plasmid DNA serves as one of the fundamental raw materials for gene-based therapy products.

Viral vector manufacturing emphasizes manufacturing functional viral particles such as lentiviruses, adeno-associated viruses (AAV), and adenoviruses. The process involves introducing genes into host cells, isolation of vectors from the host, facilitation of replication of vectors, and certification of potency and safety. Such carriers are designed for enabling the delivery of therapeutic genes effectively into the patient's cells.

Attribute	Detail
Viral Vector & Plasmid DNA Manufacturing Market Drivers	Growing Gene Therapy Pipeline Increased Clinical Trials and Therapy Approvals

Growing Gene Therapy Pipeline to Pitch the Viral Vector & Plasmid DNA Manufacturing Market Share

The gene therapy pipeline has emerged as one of the major growth drivers to the viral vector and plasmid DNA manufacturing market. As biotechnology and pharmaceutical companies advance through increasing number of gene-based therapies into commercial and clinical pipelines, the demand for high-quality vectors and plasmid DNA continues to rise. Such genetic vectors are necessary for delivering therapeutic genes, thereby making their reliable supply crucial for the success of gene therapy programs.

New therapies require proprietary viral vectors and plasmid DNA for unique gene constructs, thereby improving the complexity of production and increase the volume of materials required. This translates into manufacturers increasing scalability, capacity, and standardization in the production processes. The rise in experimental therapeutics has also raised the desire for adaptable systems that are capable of handling diverse types of vectors such as lentivirus, AAV, and adenovirus.

Moreover, the demand for personalized manufacturing solutions is witnessing an upsurge, especially for gene therapies targeting oncology and rare diseases. Product developers are increasingly seeking collaborators who can enable fast GMP-compliant production to meet the rigorous regulatory standards. This trend is driving investments in advanced bioprocessing technologies and automation tools.

Increased Clinical Trials and Therapy Approvals Influencing Viral Vector & Plasmid DNA Manufacturing Market Share

Increasing levels of gene and cell therapy product approvals and clinical trials are a key driver propelling the viral vector and plasmid DNA manufacturing market. With therapeutic products making advanced trials phases, the need for large-scale, GMP-grade manufacturing of viral vectors, and plasmid DNA increases. Such growth is associated with uniform quality, scalability, and adherence to global regulatory requirements.

Each newly approved treatment establishes elevated standards of product quality, safety, and manufacturing efficiency. Well-documented and certified procedures are required by the regulating agencies, thereby forcing manufacturers to invest in high-quality bioprocessing equipment and automation technologies. These investments enhance reproducibility and reliability in the clinical and commercial phases of manufacturing and minimizes the likelihood of bottlenecks in manufacture.

The increasing number of clinical trials is also a major factor in the diversification of manufacturing platforms, which are being designed to accommodate different vector types such as AAV, lentivirus, and adenovirus. Manufacturers are building flexible facilities that can handle various products and different batch sizes and complexities of products, thus ensuring fast supply for trials worldwide.

In conclusion, the escalation of clinical activities and product approvals is a great source of confidence for gene-based therapies and, therefore is a strong driver of the viral vector & plasmid DNA manufacturing industry growth. Besides, it allows therapy developers to enter into alliances with the contract manufacturers, thus gaining access to their technological expertise, capacity expansion, and process optimization in the viral vector and plasmid DNA manufacturing industry.

Viral Vectors Leading Global Viral Vector & Plasmid DNA Manufacturing Market

Viral Vector & Plasmid Dna Manufacturing Market By Vector Type

Viral vectors dominate the viral vector & plasmid DNA manufacturing market, serving as the primary delivery systems for most gene and cell therapies. In fact, their ability to perform therapeutic gene insertions into the target cells with high accuracy and long-term stability positions them as preferred treatment option for genetic and rare diseases.

Additionally, the utilization of viral vectors, adeno-associated viruses, and lentiviruses in the production of advanced therapies and vaccines is very significant, thereby attracting the demand for large-scale production. The ongoing innovation of vector design, the improved safety profile, as well as the unlimited number of clinical applications, are among the factors that contribute to the continued occupancy of the plasmid DNA by viral vectors in the global manufacturing landscape.

Regional Outlook of Viral Vector & Plasmid DNA Manufacturing Market

Viral Vector & Plasmid Dna Manufacturing Market By Revenue

Attribute	Detail
Leading Region	North America

As per the latest viral vector & plasmid DNA manufacturing market analysis, North America dominated the market in 2024, capturing a market share of 43.8%. This is due to the strengths of the region's biotech ecosystem, its well-established research infrastructure, and massive investments in gene therapy. The region also boasts the presence of numerous biopharmaceutical companies and research institutions. These institutions actively engage in the development of innovative gene and cell therapies and, therefore, are the main drivers of the continuous need for large-scale vector and plasmid production.

Moreover, the supportive regulatory frameworks and heavy financing from both - the public and the private sector provide excellent conditions for manufacturing. The existence of high-quality GMP facilities, a well-trained labor force, and the growing collaboration between academia and industry have all contributed to further strengthen North America's position on this rapidly expanding market.

Analysis of Key Players in Viral Vector & Plasmid DNA Manufacturing Market

The players engaged in the viral vector & plasmid DNA manufacturing market are investing heavily in automation and advanced bioprocessing technologies for enhancing production scalability and efficiency. Firms are also emphasizing developing flexible manufacturing systems to accommodate personalized therapies and several vector types.

Thermo Fisher Scientific Inc., Lonza, Hillgene Biopharma Co., Ltd., Revvity, Merck KGaA, Aldevron LLC, VGXI, FUJIFILM Biotechnologies, WuXi Biologics, Takara Bio Inc., REGENXBIO Inc., AGC Biologics, Batavia Biosciences B.V., Sanofi, and Wacker Chemie AG are some of the leading players operating in the global viral vector & plasmid DNA manufacturing market.

Each of these players has been profiled in the viral vector & plasmid DNA manufacturing market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments in Viral Vector & Plasmid DNA Manufacturing Market

In June 2025, ProBio announced the opening of its Cell and Gene Therapy Center of Excellence at Princeton West Innovation Campus in Hopewell, New Jersey. The 128,000 sq. ft. state-of-the-art GMP facility is equipped with a view to high-quality plasmid DNA and viral vector manufacturing, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms, highlighting ProBio's focus on driving the accelerated delivery of life-changing medicines.
In June 2025, ArcticZymes Technologies ASA announced the expansion of its GMP product line, with M-SAN HQ GMP, a new GMP grade nuclease for use in virus vector manufacturing. The newly launched product brought the established performance of M-SAN HQ with regulatory strength of GMP manufacturing and offered an extremely efficient enzymatic host cell DNA elimination solution under physiological salt conditions.

Viral Vector & Plasmid DNA Manufacturing Market Snapshot

Attribute	Detail
Size in 2024	US$ 4.8 Bn
Forecast Value in 2035	US$ 23.9 Bn
CAGR	15.7%
Forecast Period	2025-2035
Historical Data Available for	2020-2023
Quantitative Units	US$ Bn
Viral Vector & Plasmid DNA Manufacturing Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape	Competition Matrix Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Segmentation	Vector Type Viral Vectors Adenovirus Retrovirus Adeno-Associated Virus (AAV) Lentivirus Other Viral Vectors Plasmid DNA Workflow Upstream Manufacturing Vector Amplification, Editing & Expansion Vector Recovery/Harvesting Downstream Manufacturing Purification Fill Finish Application Cell and Gene Therapies Vaccine Development Antisense & RNAi Therapies Others (Stem cell Research, etc.) Scale of Manufacturing Preclinical Clinical Commercial End-user Pharmaceutical and Biotechnology Companies Contract Manufacturing Organizations (CMOs) Academic and Research Institutions
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain The Netherlands China Australia India Japan South Korea ASEAN Brazil Mexico Argentina GCC Countries South Africa
Companies Profiled	Thermo Fisher Scientific Inc. Lonza Hillgene Biopharma Co., Ltd. Revvity Merck KGaA Aldevron LLC VGXI FUJIFILM Biotechnologies WuXi Biologics Takara Bio Inc. REGENXBIO Inc. AGC Biologics Batavia Biosciences B.V. Sanofi Wacker Chemie AG
Customization Scope	Available upon request
Pricing	Available upon request

Frequently Asked Questions

How big was the global viral vector & plasmid DNA manufacturing market in 2024?

The global viral vector & plasmid DNA manufacturing market was valued at US$ 4.8 Bn in 2024

How big will the global viral vector & plasmid DNA manufacturing industry be in 2035?

The global viral vector & plasmid DNA manufacturing industry is projected to reach more than US$ 23.9 Bn by the end of 2035

What are the factors driving the viral vector & plasmid DNA manufacturing market?

The increasing adoption of gene therapies for treatment of genetic and rare disorders, technological advancements in manufacturing processes, growing clinical trials and market approvals for gene-based products, increased investment in biotechnology, and the growing need for novel vaccine development are some of the factors driving the expansion of viral vector & plasmid DNA manufacturing market.

What will be the CAGR of the global viral vector & plasmid DNA manufacturing industry during the forecast period?

The CAGR is anticipated to be 15.7% from 2025 to 2035

Who are the prominent players in the global viral vector & plasmid DNA manufacturing market?

Preface
- Market Definition and Scope
- Market Segmentation
- Key Research Objectives
- Research Highlights
Assumptions and Research Methodology
Executive Summary: Global Viral Vector & Plasmid DNA Manufacturing Market
Market Overview
- Introduction
  - Segment Definition
- Overview
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, 2020 - 2035
  - Market Revenue Projections (US$ Bn)
Key Insights
- Healthcare Expenditure across Key Countries / Regions
- Applications of Viral Vector & Plasmid DNA across Healthcare Continuum
- Recent Advancements in Viral Vector & Plasmid DNA Manufacturing
- Regulatory Scenario across Key Regions / Countries
- PORTER’s Five Forces Analysis
- PESTLE Analysis
- Go-to-Market Strategy for New Market Entrants
- Key Purchase Metrics for End-users
- Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
- Benchmarking of the Services Offered by the Leading Competitors
Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Vector Type
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Vector Type, 2020 - 2035
  - Viral Vectors
    - Adenovirus
    - Retrovirus
    - Adeno-Associated Virus (AAV)
    - Lentivirus
    - Other Viral Vectors
  - Plasmid DNA
- Market Attractiveness Analysis, by Vector Type
Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Workflow
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Workflow, 2020 - 2035
  - Upstream Manufacturing
    - Vector Amplification, Editing & Expansion
    - Vector Recovery/Harvesting
  - Downstream Manufacturing
    - Purification
    - Fill Finish
- Market Attractiveness Analysis, by Workflow
Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Application
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Application, 2020 - 2035
  - Cell and Gene Therapies
  - Vaccine Development
  - Antisense & RNAi Therapies
  - Others
- Market Attractiveness Analysis, by Application
Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Scale of
Manufacturing
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Scale of Manufacturing, 2020 - 2035
  - Preclinical
  - Clinical
  - Commercial
- Market Attractiveness Analysis, by Scale of Manufacturing
Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by End-user
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by End-user, 2020 - 2035
  - Pharmaceutical and Biotechnology Companies
  - Contract Manufacturing Organizations (CMOs)
  - Academic and Research Institutions
- Market Attractiveness Analysis, by End-user
Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Region
- Key Findings
- Market Value Forecast, by Region, 2020 - 2035
  - North America
  - Europe
  - Asia Pacific
  - Latin America
  - Middle East & Africa
- Market Attractiveness Analysis, by Region
North America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Vector Type, 2020 - 2035
  - Viral Vectors
    - Adenovirus
    - Retrovirus
    - Adeno-Associated Virus (AAV)
    - Lentivirus
    - Other Viral Vectors
  - Plasmid DNA
- Market Value Forecast, by Workflow, 2020 - 2035
  - Upstream Manufacturing
    - Vector Amplification, Editing & Expansion
    - Vector Recovery/Harvesting
  - Downstream Manufacturing
    - Purification
    - Fill Finish
- Market Value Forecast, by Application, 2020 - 2035
  - Cell and Gene Therapies
  - Vaccine Development
  - Antisense & RNAi Therapies
  - Others
- Market Value Forecast, by Scale of Manufacturing, 2020 - 2035
  - Preclinical
  - Clinical
  - Commercial
- Market Value Forecast, by End-user, 2020 - 2035
  - Pharmaceutical and Biotechnology Companies
  - Contract Manufacturing Organizations (CMOs)
  - Academic and Research Institutions
- Market Value Forecast, by Country, 2020 - 2035
  - U.S.
  - Canada
- Market Attractiveness Analysis
  - By Vector Type
  - By Workflow
  - By Application
  - By Scale of Manufacturing
  - By End-user
  - By Country
Europe Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Vector Type, 2020 - 2035
  - Viral Vectors
    - Adenovirus
    - Retrovirus
    - Adeno-Associated Virus (AAV)
    - Lentivirus
    - Other Viral Vectors
  - Plasmid DNA
- Market Value Forecast, by Workflow, 2020 - 2035
  - Upstream Manufacturing
    - Vector Amplification, Editing & Expansion
    - Vector Recovery/Harvesting
  - Downstream Manufacturing
    - Purification
    - Fill Finish
- Market Value Forecast, by Application, 2020 - 2035
  - Cell and Gene Therapies
  - Vaccine Development
  - Antisense & RNAi Therapies
  - Others
- Market Value Forecast, by Scale of Manufacturing, 2020 - 2035
  - Preclinical
  - Clinical
  - Commercial
- Market Value Forecast, by End-user, 2020 - 2035
  - Pharmaceutical and Biotechnology Companies
  - Contract Manufacturing Organizations (CMOs)
  - Academic and Research Institutions
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - UK
  - Germany
  - France
  - Italy
  - Spain
  - The Netherlands
  - Rest of Europe
- Market Attractiveness Analysis
  - By Vector Type
  - By Workflow
  - By Application
  - By Scale of Manufacturing
  - By End-user
  - By Country/Sub-region
Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Vector Type, 2020 - 2035
  - Viral Vectors
    - Adenovirus
    - Retrovirus
    - Adeno-Associated Virus (AAV)
    - Lentivirus
    - Other Viral Vectors
  - Plasmid DNA
- Market Value Forecast, by Workflow, 2020 - 2035
  - Upstream Manufacturing
    - Vector Amplification, Editing & Expansion
    - Vector Recovery/Harvesting
  - Downstream Manufacturing
    - Purification
    - Fill Finish
- Market Value Forecast, by Application, 2020 - 2035
  - Cell and Gene Therapies
  - Vaccine Development
  - Antisense & RNAi Therapies
  - Others
- Market Value Forecast, by Scale of Manufacturing, 2020 - 2035
  - Preclinical
  - Clinical
  - Commercial
- Market Value Forecast, by End-user, 2020 - 2035
  - Pharmaceutical and Biotechnology Companies
  - Contract Manufacturing Organizations (CMOs)
  - Academic and Research Institutions
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Market Attractiveness Analysis
  - By Vector Type
  - By Workflow
  - By Application
  - By Scale of Manufacturing
  - By End-user
  - By Country/Sub-region
Latin America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Vector Type, 2020 - 2035
  - Viral Vectors
    - Adenovirus
    - Retrovirus
    - Adeno-Associated Virus (AAV)
    - Lentivirus
    - Other Viral Vectors
  - Plasmid DNA
- Market Value Forecast, by Workflow, 2020 - 2035
  - Upstream Manufacturing
    - Vector Amplification, Editing & Expansion
    - Vector Recovery/Harvesting
  - Downstream Manufacturing
    - Purification
    - Fill Finish
- Market Value Forecast, by Application, 2020 - 2035
  - Cell and Gene Therapies
  - Vaccine Development
  - Antisense & RNAi Therapies
  - Others
- Market Value Forecast, by Scale of Manufacturing, 2020 - 2035
  - Preclinical
  - Clinical
  - Commercial
- Market Value Forecast, by End-user, 2020 - 2035
  - Pharmaceutical and Biotechnology Companies
  - Contract Manufacturing Organizations (CMOs)
  - Academic and Research Institutions
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Market Attractiveness Analysis
  - By Vector Type
  - By Workflow
  - By Application
  - By Scale of Manufacturing
  - By End-user
  - By Country/Sub-region
Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Vector Type, 2020 - 2035
  - Viral Vectors
    - Adenovirus
    - Retrovirus
    - Adeno-Associated Virus (AAV)
    - Lentivirus
    - Other Viral Vectors
  - Plasmid DNA
- Market Value Forecast, by Workflow, 2020 - 2035
  - Upstream Manufacturing
    - Vector Amplification, Editing & Expansion
    - Vector Recovery/Harvesting
  - Downstream Manufacturing
    - Purification
    - Fill Finish
- Market Value Forecast, by Application, 2020 - 2035
  - Cell and Gene Therapies
  - Vaccine Development
  - Antisense & RNAi Therapies
  - Others
- Market Value Forecast, by Scale of Manufacturing, 2020 - 2035
  - Preclinical
  - Clinical
  - Commercial
- Market Value Forecast, by End-user, 2020 - 2035
  - Pharmaceutical and Biotechnology Companies
  - Contract Manufacturing Organizations (CMOs)
  - Academic and Research Institutions
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - GCC Countries
  - South Africa
  - Rest of Middle East & Africa
- Market Attractiveness Analysis
  - By Vector Type
  - By Workflow
  - By Application
  - By Scale of Manufacturing
  - By End-user
  - By Country/Sub-region
Competition Landscape
- Market Player - Competition Matrix (By Tier and Size of Companies)
- Market Share Analysis, by Company (2024)
- Company Profiles
  - Thermo Fisher Scientific Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Lonza
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Hillgene Biopharma Co., Ltd.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Revvity
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Merck KGaA
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Aldevron LLC
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - VGXI
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - FUJIFILM Biotechnologies
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - WuXi Biologics
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Takara Bio Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - REGENXBIO Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - AGC Biologics
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Batavia Biosciences B.V.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Sanofi
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Wacker Chemie AG
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments

List of Tables

Table 01: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Vector Type, 2020 to 2035
Table 02: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Viral Vectors, 2020 to 2035
Table 03: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Workflow, 2020 to 2035
Table 04: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Upstream Manufacturing, 2020 to 2035
Table 05: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Downstream Manufacturing, 2020 to 2035x
Table 06: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 07: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Scale of Manufacturing, 2020 to 2035
Table 08: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 09: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 10: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, by Country, 2020-2035
Table 11: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Vector Type, 2020 to 2035
Table 12: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Viral Vectors, 2020 to 2035
Table 13: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Workflow, 2020 to 2035
Table 14: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Upstream Manufacturing, 2020 to 2035
Table 15: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Downstream Manufacturing, 2020 to 2035
Table 16: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 17: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Scale of Manufacturing, 2020 to 2035
Table 18: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 19: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 20: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Vector Type, 2020 to 2035
Table 21: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Viral Vectors, 2020 to 2035
Table 22: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Workflow, 2020 to 2035
Table 23: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Upstream Manufacturing, 2020 to 2035
Table 24: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Downstream Manufacturing, 2020 to 2035
Table 25: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 26: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Scale of Manufacturing, 2020 to 2035
Table 27: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 28: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 29: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Vector Type, 2020 to 2035
Table 30: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Viral Vectors, 2020 to 2035
Table 31: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Workflow, 2020 to 2035
Table 32: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Upstream Manufacturing, 2020 to 2035
Table 33: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Downstream Manufacturing, 2020 to 2035
Table 34: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 35: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Scale of Manufacturing, 2020 to 2035
Table 36: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 37: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 38: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Vector Type, 2020 to 2035
Table 39: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Viral Vectors, 2020 to 2035
Table 40: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Workflow, 2020 to 2035
Table 41: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Upstream Manufacturing, 2020 to 2035
Table 42: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Downstream Manufacturing, 2020 to 2035
Table 43: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 44: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Scale of Manufacturing, 2020 to 2035
Table 45: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 46: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2035
Table 47: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Vector Type, 2020 to 2035
Table 48: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Viral Vectors, 2020 to 2035
Table 49: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Workflow, 2020 to 2035
Table 50: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Upstream Manufacturing, 2020 to 2035
Table 51: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Downstream Manufacturing, 2020 to 2035
Table 52: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
Table 53: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By Scale of Manufacturing, 2020 to 2035
Table 54: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035

List of Figures

Figure 01: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Vector Type, 2024 and 2035
Figure 02: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Vector Type, 2025 to 2035
Figure 03: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Viral Vectors, 2020 to 2035
Figure 04: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Plasmid DNA, 2020 to 2035
Figure 05: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Workflow, 2024 and 2035
Figure 06: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Workflow, 2025 to 2035
Figure 07: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Upstream Manufacturing, 2020 to 2035
Figure 08: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Downstream Manufacturing, 2020 to 2035
Figure 09: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Application, 2024 and 2035
Figure 10: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 11: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Cell and Gene Therapies, 2020 to 2035
Figure 12: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Vaccine Development, 2020 to 2035
Figure 13: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Antisense & RNAi Therapies, 2020 to 2035
Figure 14: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 15: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Scale of Manufacturing, 2024 and 2035
Figure 16: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Scale of Manufacturing, 2025 to 2035
Figure 17: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Preclinical, 2020 to 2035
Figure 18: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Clinical, 2020 to 2035
Figure 19: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Commercial, 2020 to 2035
Figure 20: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 21: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 22: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Pharmaceutical and Biotechnology Companies, 2020 to 2035
Figure 23: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Contract Manufacturing Organizations (CMOs), 2020 to 2035
Figure 24: Global Viral Vector & Plasmid DNA Manufacturing Market Revenue (US$ Bn), by Academic and Research Institutions, 2020 to 2035
Figure 25: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Region, 2024 and 2035
Figure 26: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 27: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 28: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, by Country, 2024 and 2035
Figure 29: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 30: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Vector Type, 2024 and 2035
Figure 31: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Vector Type, 2025 to 2035
Figure 32: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Workflow, 2024 and 2035
Figure 33: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Workflow, 2025 to 2035
Figure 34: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Application, 2024 and 2035
Figure 35: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 36: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Scale of Manufacturing, 2024 and 2035
Figure 37: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Scale of Manufacturing, 2025 to 2035
Figure 38: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 39: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 40: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 41: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 42: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 43: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Vector Type, 2024 and 2035
Figure 44: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Vector Type, 2025 to 2035
Figure 45: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Workflow, 2024 and 2035
Figure 46: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Workflow, 2025 to 2035
Figure 47: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Application, 2024 and 2035
Figure 48: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 49: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Scale of Manufacturing, 2024 and 2035
Figure 50: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Scale of Manufacturing, 2025 to 2035
Figure 51: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 52: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 53: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 54: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 55: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 56: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Vector Type, 2024 and 2035
Figure 57: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Vector Type, 2025 to 2035
Figure 58: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Workflow, 2024 and 2035
Figure 59: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Workflow, 2025 to 2035
Figure 60: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Application, 2024 and 2035
Figure 61: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 62: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Scale of Manufacturing, 2024 and 2035
Figure 63: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Scale of Manufacturing, 2025 to 2035
Figure 64: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 65: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 66: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 67: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 68: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 69: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Vector Type, 2024 and 2035
Figure 70: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Vector Type, 2025 to 2035
Figure 71: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Workflow, 2024 and 2035
Figure 72: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Workflow, 2025 to 2035
Figure 73: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Application, 2024 and 2035
Figure 74: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 75: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Scale of Manufacturing, 2024 and 2035
Figure 76: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Scale of Manufacturing, 2025 to 2035
Figure 77: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 78: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 79: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 80: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 81: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 82: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Vector Type, 2024 and 2035
Figure 83: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Vector Type, 2025 to 2035
Figure 84: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Workflow, 2024 and 2035
Figure 85: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Workflow, 2025 to 2035
Figure 86: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Application, 2024 and 2035
Figure 87: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 88: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By Scale of Manufacturing, 2024 and 2035
Figure 89: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By Scale of Manufacturing, 2025 to 2035
Figure 90: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share Analysis, By End-user, 2024 and 2035
Figure 91: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis, By End-user, 2025 to 2035